The destruction and rebuilding of the extracellular matrix in the pathogenesis of acute focal cerebral ischemia

Cover Page

Cite item

Full Text

Abstract

The review presents the current view of the part of matrix metalloproteinases (MMPs) in the pathogenesis of ischemic stroke. It describes the main types of MMP, the function of which is related to the exchange of connective tissue matrix in normal and pathological conditions. Describe the role of MMPs in the development of atherothrombosis. It is shown that one of the factors that lead to the damage of plaque, is to increase the IMF, particularly pronounced in the most vulnerable areas of plaque - the shoulder. On the other hand, revealed the properties of MMP strengthen tire atherosclerosis plaque. Transmitted by the level of circulating MMP-9 is associated with the progression of atherosclerosis and the risk of cardiovascular events. The results of experimental and clinical studies on the role of MMP-9 in acute cerebral ischemia are generalized. Shown to increase MMP-9 in the first hours of acute ischemia in the lesion and in peripheral blood serum. Presents the multidirectional action of MMP-9 in the pathogenesis of acute focal cerebral ischemia. Described the group of drugs acting on the level of MMP-9.

About the authors

E. V Konstantinova

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: katekons@mail.ru
д-р мед. наук, доц. каф. факультетской терапии им. акад. А.И.Нестерова ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

M. Kh Shurdumova

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: dr_shurdumova@mail.ru
канд. мед. наук, ассистент каф. фундаментальной и клинической неврологии и нейрохирургии ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

References

  1. Чазов Е.И., Кухарчук В.В., Бойцова С.А. Руководство по атеросклерозу и ишемической болезни сердца. М.: Медиа Медика, 2007; с. 232.
  2. Peeters W, Hellings W.E, de Kleijn D.P.V et al. Carotid atherosclerotic plaques stabilize after stroke insights into the natural process of atherosclerotic plaque stabilization. Arterioscler Thromb Vasc Biol 2009; 29: 128-33.
  3. Redgrave J.N, Lovett J.K, Gallagher P.J. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation 2006; 113: 2320-8.
  4. Gasche Y, Soccal P.M, Kanemitsu M. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci 2006; 11: 1289-301.
  5. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290-308.
  6. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.
  7. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-342.
  8. Galis Z.S, Sukhova G.K, Lark M.W. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
  9. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008; 28: 2108-14.
  10. Dollery C.M, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69: 625-35.
  11. Johnson C, Galis Z.S. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell - mediated collagen organization. Arterioscler Thromb Vase Biol 2004; 24: 54-60.
  12. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005: 85: 1-31.
  13. Abdelnaseer M, Elfayomi N, Esmail E.H et al. Relationship between matrix metalloproteinase-9 and common carotid artery intima media thickness. Neurol Sci 2015; Aug 30.
  14. Stuijter J.P, Pulskens W.P, Schoneveld A.H et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinases inducer glycosylation forms. Stroke 2006; 37: 235-9.
  15. Abelleira S, Bevan S, Markus H. Matrix metalloproteinases. J Med Genet 2006; 43: 897-901.
  16. Kaplan R.C, Smith N.L, Zucker S. Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis 2008; 201: 130-7.
  17. Eldrup N, Gronholdt M.L, Sillesen H. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006; 114: 1847-54.
  18. Welsh P, Whincup P.H, Papacosta O. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle - aged men. QJM 2008; 101: 785-91.
  19. Копица Н.П., Белая Н.В., Титаренко Н.В. Роль матриксных металлопротеиназ в патогенезе постинфарктного ремоделирования левого желудочка. Междунар. мед. журн. 2010; 4: 55-58.
  20. Cunningham L.A, Wetzel M, Rosenberg G.A. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50: 329-39.
  21. Rosell A, Ortega-Aznar A. Alvarez-Sabin J et al. Increased brain expression of Matrix Metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399-406.
  22. Egashira Y, Zhao H, Hua Y et al. White Matter Injury After Subarachnoid Hemorrhage: Role of Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9. Stroke 2015; 46 (10): 2909-5.
  23. Cadenas I, Ribo M, Molina C.A et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399-406.
  24. Zhao B.Q, Ikeda Y, Ihara H et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparinproduced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004; 103: 2610-6.
  25. Rosell A., Cuadrado E, Ortega-Aznar A. Mmp-9-positive neutrophil infiltration is associated to blood - brain barrier breakdown and basal lamina type iv collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121-6.
  26. Romanic A.M, White R.F, Arleth A.J et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 5: 1020-30.
  27. Planas A.M, Sole S, Justicia C. Expression and activation of matrix metalloproteinase- 2 and-9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001; 8: 834-46.
  28. Koh S.H, Chang D.I, Kim H.T et al. Effect of 3-aminobenzamide, parp inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology 2005; 214: 131-9.
  29. Park K.P, Rossel A, Foerch C et al. Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke 2009; 40 (8): 2836-42.
  30. Asahi M, Asahi K, Jung J.C et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20: 1681-9.
  31. Asahi M, Wang X, Mori T et al. Effects of matrix metalloproteinase-9 gene knockout on the proteolysis of blood - brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-32.
  32. Gu Z, Kaul M, Yan B et al. S-nitrosylation of matrix metalloproteinases: Signaling pathway to neuronal cell death. Science 2002; 297: 1186-90.
  33. Lee S.R, Lo E.H. Induction of caspase - mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia - reoxygenation. J Cereb Blood Flow Metab 2004; 24: 720-7.
  34. Copin J.C, Merlani P, Sugawara Т et al. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol 2008; 213: 196-201.
  35. Liu X.S, Chopp M, Zhang R.L. Angiopoietin 2 mediates the differentiation and migration of neural progenitor cells in the subventricular zone after stroke. J Biol Chem 2009; 284 (34): 22680-9.
  36. Lee S.R, Kim H.Y, Rogowska J et al. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci 2006; 26: 3491-5.
  37. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009: 8: 205-16.
  38. Montaner J, Alvarez-Sabin J, Molina C.A et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32: 2762-7.
  39. Montaner J, Rovira A, Molina C.A et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion - weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 2003; 23: 1403-7.
  40. Horstmann S, Kalb P, Koziol J et al. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: Influence of different therapies. Stroke 2003; 34: 2165-70.
  41. Шамалов Н.А., Скворцова В.И., Рамазанов Г.Р. и др. Компьютерно - томографические и биохимические предикторы исходов тромболитической терапии у пациентов с ишемическим инсультом. Журн. неврологии и психиатрии им. С.С.Корсакова. 2010; 4: 21-8.
  42. Coussens L.M, Fingleton B, Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
  43. Гусев Е.И., Коновалов А.Н., Скворцова В.И., Гехт А.Б. Неврология: Национальное руководство. М.: ГЭОТАР-Медиа, 2009; с. 592-615.
  44. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25 (5): 457-507.
  45. Suzuki Y. Role of tissue - type plasminogen activator in ischemic stroke. J Pharmacol Sci 2010; 113: 203-7.
  46. Suzuki Y, Nagai N, Umemura K et al. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 2007; 5: 1732-9.
  47. Hosomi N, Nishiyama A, Ban C.R et al. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005; 134: 225-31.
  48. Tanaka H, Takai S, Jin D et al. Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens Res 2007; 5: 469-75.
  49. Liebetrau M, Burggraf D, Wunderlich N et al. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke - prone rats. Neurosci Lett 2005; 376: 205-9.
  50. Miyazaki S, Kasai T, Miyauchi K et al. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circulation 2010; 74: 1158-64.
  51. Hayashidani S, Tsutsui H, Shiomi T et al. Fluvastatin, a 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodelling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-73.
  52. Luan Z, Chase A.J, Newby A.C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vas Biol 2003; 23: 769-75.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies